我国医药行业企业的研发投入与绩效研究

发布时间：2018-03-04 12:24

  本文选题：医药行业　切入点：研发投入强度　出处：《对外经济贸易大学》2017年硕士论文　论文类型：学位论文

【摘要】：伴随着全球经济和科技的发展,医药行业的发展也在不断推进,不论是发达国家还是发展中国家,作为支柱产业之一的医药行业都蕴含着巨大的经济及社会效益。我国作为发展中国家,医药行业尤其是西药方面起步要晚于欧美这样发达的国家,在研发方面与欧美相比还有一定差距,但近年来亦快速增长。早在20世纪,美国医药研发就已经具有一定规模,其研发主要集中在加州、华盛顿和新英格兰地区,在美国加州聚集2500家生物医学公司、至少75所大学和非盈利的私人研究机构专门从事医药研发。在美国,大约有80%的研发活动投入在新药发明,18%的研发活动投入在现有产品的改进,67%的成本花费在新药开发阶段。我国目前还是有很多医药企业以仿制药品为主,利用成本差异来抢占一定的市场份额,但是这样的形式不利于企业发展,不利于企业研发能力的提升,也不利于我国医药行业的前进。本文通过实践研究,就“我国医药行业企业的研发投入对绩效产生的影响”进行分析,得出如下结论:本文选取83家在我国证券交易所上市的医药制药公司,其中西药上市公司有70家,生物医药公司13家,翻阅其2011年到2015年的年度报告及Wind资讯,将研发投入金额、研发支出费用化支出和研发支出资本化支出的数据作为自变量,企业的绩效指标作为因变量,将资产负债率、企业规模、营业收入增长率、总资产周转率作为控制变量,通过相关性检测和多元回归分析得出我国医药行业的研发投入总额与企业绩效有正相关关系,研发支出费用化支出对企业的绩效具有正向促进作用,说明研发活动的创新结果能够提高企业的收益,但研发支出资本化支出与企业绩效的相关关系较弱,说明自主创新的成果还不够多。鉴于此,本文建议:从政府层面,国家就医药行业研发投入提供政策支持和相关优惠、鼓励医药行业的发展、加强上市公司研发信息的披露、完善我国企业与国外企业研发合作的政策建设;从企业层面,响应国家号召,加强科技创新意识、加强与研究机构的合作、加强创新项目的管理,不断提升研发水平和速度,并视其为可持续发展的基础,加大研发的资金投入,进一步增强企业自主创新能力。
[Abstract]:With the development of the global economy and science and technology, the development of the pharmaceutical industry is also advancing, whether developed or developing countries, As one of the pillar industries, the pharmaceutical industry has enormous economic and social benefits. As a developing country, China's pharmaceutical industry, especially Western medicine, started later than developed countries such as Europe and America. There is still a gap in R & D compared with Europe and the United States, but it has also grown rapidly in recent years. As early as 20th century, pharmaceutical R & D in the United States was already on a certain scale, mainly concentrated in California, Washington, and New England. In California, where 2,500 biomedical companies, at least 75 universities and non-profit private research institutions specialize in pharmaceutical research and development. About 80% of the R & D activities are invested in the development of new drugs, 18% of the R & D activities are invested in the improvement of existing products, 67% of the cost is spent on the stage of new drug development. At present, there are still many pharmaceutical enterprises in our country mainly focusing on imitation drugs. The use of cost differences to seize a certain market share, but this form is not conducive to the development of enterprises, enterprise R & D capabilities are not conducive to the advancement of China's pharmaceutical industry. Based on the analysis of the impact of R & D investment on the performance of Chinese pharmaceutical enterprises, the following conclusions are drawn: this paper selects 83 pharmaceutical companies listed on Chinese stock exchanges, of which 70 are listed in western medicine companies. Thirteen biomedical companies, looking through their annual reports from 2011 to 2015 and Wind information, take the data of R & D expenditure, R & D expenditure and R & D expenditure capitalization as independent variables, and the performance indicators of enterprises as dependent variables. Taking asset-liability ratio, enterprise scale, growth rate of operating income and total asset turnover as control variables, it is found that there is a positive correlation between total R & D investment and enterprise performance in China's pharmaceutical industry through correlation testing and multiple regression analysis. The positive effect of R & D expenditure on enterprise performance shows that the innovation result of R & D can improve the enterprise's income, but the correlation between R & D expenditure capitalization expenditure and enterprise performance is weak. In view of this, this paper suggests that, at the government level, the state should provide policy support and related preferential treatment for R & D investment in the pharmaceutical industry, encourage the development of the pharmaceutical industry, and strengthen the disclosure of R & D information of listed companies. Improve the policy construction of R & D cooperation between Chinese enterprises and foreign enterprises, strengthen the awareness of scientific and technological innovation, strengthen cooperation with research institutions, strengthen the management of innovative projects, and continuously improve the level and speed of R & D from the enterprise level, in response to the call of the state, Regard it as the foundation of sustainable development, increase the investment of R & D, and further strengthen the independent innovation ability of enterprises.
【学位授予单位】：对外经济贸易大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：F426.72;F273.1;F406.7
，

本文编号：1565638